The most important aspects during the treatment with Sacituzumab Govitecan are not just taking the infusion at the timely schedules, but knowing the minute details of it such as when to use it, dosage recommendations and expected signs are equally important. This article guides you through these aspects.
Patients prescribed the 180 mg presentation can refer to Sacituzumab Govitecan 180 mg for product-specific information. For those requiring sacituzumab govitecan in India, it is important to understand its uses, dosage, and safety considerations before starting treatment.
Uses of Sacituzumab Govitecan
It is used specifically for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have already received a minimum of two therapies for metastatic disease.
Dosage guidelines
Premedication
- Premedication is important to take before the Sacituzumab infusion for prevention of infusion reactions and prevention of chemotherapy-induced nausea and vomiting (CINV).
- Premedicate with antipyretics, H1 and H2 blockers prior to infusion, and corticosteroids may be used for patients who had prior infusion reactions.
- Premedicate with a two or three drug combination regimen (e.g., dexamethasone with either a 5-HT3 receptor antagonist or an NK1 receptor antagonist, as well as other drugs as indicated).
Right dosage:
- The recommended dosage of Sacituzumab Govitecan is 10mg/kg administered as an intravenous infusion once weekly on Days 1 and 8 of 21-day treatment cycles. Proceed with this therapy until disease progression or unacceptable toxicity.
Precautions while Infusing:
- Do not administer the medication at doses greater than 10 mg/kg.
- The route of administration should be as an intravenous infusion only, but not an intravenous push or bolus.
- Make sure to administer infusion over 3 hours during the first infusion. Observe patients during the infusion and for at least 30 minutes following the initial dose, for signs or symptoms of infusion-related reactions.
- In the subsequent infusions, administer infusion over 1 to 2 hours if prior infusions were tolerated. Monitor patients during the infusion and for at least 30 minutes after infusion.
Note: FDA has made a strict prohibition of substitution of Sacituzumab Govitecan for or use with other drugs containing irinotecan or its active metabolite SN-38.
Patient counselling
1. Neutropenia
Neutropenia is a high alert for the patients receiving Sacituzumab because it is a life-threatening condition. Pause the medication for absolute neutrophil count below 1500/mm3 or neutropenic fever. Monitor blood cell counts periodically during treatment. Consider granulocyte colony stimulating factor (G-CSF) for secondary prophylaxis. Initiate anti-infective treatment in patients with febrile neutropenia without delay.
For a more detailed discussion of treatment-related signals, read the Sacituzumab Govitecan therapy and treatment signals guide.
2. Diarrhoea
Sacituzumab can cause severe diarrhoea. Pause Sacituzumab for Grade 3-4 diarrhea at the time of scheduled treatment administration and resume when resolved to ≤ Grade 1. At the onset of diarrhea, evaluate for infectious causes and if negative, promptly initiate loperamide, 4 mg initially followed by 2 mg with every episode of diarrhea for a maximum of 16 mg daily. Discontinue loperamide 12 hours after diarrhea resolves. Fluid and electrolyte substitution may also be employed according to the health condition. Patients who exhibit an excessive cholinergic response to treatment such as abdominal cramping, diarrhea, salivation during the treatment can receive atropine as a premedication for next treatments.
3. Hypersensitivity
Reports mention the cases of hypersensitivity in patients receiving Sacituzumab. Hence pre-infusion medication is required. Observe patients closely for infusion-related reactions during each infusion and for at least 30 minutes after completion of each infusion. Medication to treat such reactions, as well as emergency equipment, should be available for immediate use.
For additional information about the medicine and its potential side effects, refer to the Trodelvy (Sacituzumab Govitecan) in India: Uses & Side Effects.
4. Nausea and vomiting
As Sacituzumab is emotogenic, it is best to premedicate with a two or three drug combination regimen (e.g., dexamethasone with either a 5-HT3 receptor antagonist or an NK-1 receptor antagonist as well as other drugs as indicated) for prevention of chemotherapy-induced nausea and vomiting (CINV). Pause the Sacituzumab doses for Grade 3 nausea or Grade 3-4 vomiting at the time of scheduled treatment administration and resume with additional supportive measures when resolved to Grade ≤ 1. Alongside these modifications, antiemetics and other supportive measures are also recommended according to the patient’s condition.
Although all the symptoms are monitored, neutropenia and diarrhoea are carefully monitored for its symptoms because of its severity and harmful effects. Patients researching treatment access can also refer to the Sacituzumab Govitecan price and access in India guide for additional information. Contact us at 24/7QualityMeds for the healthcare content, guidance on how to Buy sacituzumab govitecan in India and the safe legal import assistance.
